Insmed Reports Issuance of Two Patents
September 11, 2013 at 07:34 AM EDT
Insmed Incorporated (NASDAQ: INSM ), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, announces two important patent allowances in the U.S. and Europe that strengthen the Company's global patent portfolio. Insmed is focused on the development and commercialization of